1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose.

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose.

Item
http://www.wikidata.org/entity/Q53157941
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.Osimertinib for the treatment of non-small cell lung cancer.New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First LineThe resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.Urine test for EGFR analysis in patients with non-small cell lung cancer.Third generation EGFR TKIs: current data and future directions.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.Olmutinib: First Global Approval.[Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer].
P2860

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose.

Item
http://www.wikidata.org/entity/Q53157941
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
1300: Efficacy and safety of B ...... the recommended phase II dose.
@en
1300: Efficacy and safety of B ...... the recommended phase II dose.
@nl
type
label
1300: Efficacy and safety of B ...... the recommended phase II dose.
@en
1300: Efficacy and safety of B ...... the recommended phase II dose.
@nl
prefLabel
1300: Efficacy and safety of B ...... the recommended phase II dose.
@en
1300: Efficacy and safety of B ...... the recommended phase II dose.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
1300: Efficacy and safety of B ...... the recommended phase II dose.
@en
P2093
P304
P31
P356
10.1016/S1556-0864(16)30243-X
P433
P478
P577
P698